Phastar has had its net-zero target approved by the Science Based Targets initiative (SBTi). The SBTi is a global body enabling businesses to set ambitious emissions reductions targets in line with the latest climate science and is considered the gold standard for net-zero.
A component of Phastar’s commitment to SBTi is the pledge to achieve the Science Based Targets initiative (SBTi) Net-Zero Standard by 2035. By adopting stringent sustainability standards, Phastar aims to reduce its carbon footprint, engage with stakeholders, and promote responsible business practices.
In a press release, Phastar Chief Executive Officer Graham Clark said: “Having our net-zero target approved by the SBTi underscores our commitment to corporate responsibility and sustainable business practices. As a company, we pride ourselves on our mission to make a meaningful difference in the world, and on being a great company to work with and work for."
Phastar has already taken steps to hit net zero by 2035. Measures taken so far include strengthening the company’s emissions-measurement processes to enable more easy tracking. The organization has also developed and launched a sustainability strategy to outline exactly how it will reduce its emissions, as well as help its suppliers to do the same. Phastar also plans to roll out policies, initiatives, and incentives throughout its global team to help it become a more environmentally friendly business.
Clark continued, “Our net-zero by 2035 target is well ahead of industry norms and demonstrates Phastar’s dedication to reducing our carbon emissions. No one organization can tackle climate change alone, meaning we all must work together if we are to succeed. During our work so far, we have been extremely encouraged to find that many of our partners and clients already share our business values in this regard. We believe this will, ultimately, drive faster change."
Phastar Net-Zero Target Approved by the Science Based Targets Initiative. (2023, October 4). Phastar.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Real-World Data Show 99% Efficacy for Apretude in HIV Prevention with High Adherence, Reduced Stigma
October 16th 2024Real-world data presented at IDWeek 2024 show Apretude (cabotegravir long-acting) is more than 99% effective in preventing HIV infection, with high adherence rates, reduced stigma and anxiety, and broad acceptability.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.